Table 5.

Effects of erlotinib and/or naproxen in the prevention of bladder cancer when agents were started 1 month after final OH-BBN treatment.

Urinary bladder cancers
GroupNumber of ratsCarcinogenTreatmentIncidenceMultiplicityWeight (mg)Number greater than 200 mg
121OH-BBNErlotinib, 42 mg/kg BW, 1x/week86%(14%↓)a,b2.38 (56%↓)c,d475 (43%↓)a,d,e57% (37%↓)a,b
221OH-BBNNaproxen, 128 mg/kg diet95%(5%↓)a,b2.67 (50%↓)c,d186 (78%↓)b,c29% (68%↓)c
320OH-BBNErlotinib + Naproxen (as indicated for groups 1 and 2)50%(50%↓)c0.80 (85%↓)c146 (82%↓)c15% (83%↓)c
421OH-BBNNone100%5.3883290%
  • Note: Female Fischer-344 rats received OH-BBN for 8 weeks beginning at 56 days of age. Administration of Erlotinib and/or Naproxen initiated 1 month after final OH-BBN treatment. Study terminated 10 months after the initial OH-BBN treatment.

  • aStatistically significant from the control group (group 4) at P ≤ 0.05.

  • bStatistically significant from the combination group (group 3) at P ≤ 0.01.

  • cStatistically significant from the control group (group 4) at P ≤ 0.0001.

  • dStatistically significant from the combination group (group 3) at P ≤ 0.001.

  • dStatistically significant from group 2 (P = 0.0452).